Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Yamo Deniz purchased 1,000 shares of Flexion Therapeutics stock in a transaction that occurred on Tuesday, September 5th. The shares were bought at an average cost of $24.20 per share, for a total transaction of $24,200.00. Following the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $121,000. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Yamo Deniz also recently made the following trade(s):

  • On Friday, September 1st, Yamo Deniz purchased 3,000 shares of Flexion Therapeutics stock. The shares were bought at an average cost of $24.15 per share, for a total transaction of $72,450.00.
  • On Thursday, August 31st, Yamo Deniz purchased 1,375 shares of Flexion Therapeutics stock. The shares were bought at an average cost of $25.40 per share, for a total transaction of $34,925.00.

Shares of Flexion Therapeutics, Inc. (NASDAQ FLXN) traded up 2.16% during midday trading on Friday, hitting $24.12. The company’s stock had a trading volume of 732,733 shares. Flexion Therapeutics, Inc. has a 52-week low of $15.88 and a 52-week high of $29.41. The firm’s market cap is $769.55 million. The stock’s 50 day moving average is $23.24 and its 200-day moving average is $21.99.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Equities analysts predict that Flexion Therapeutics, Inc. will post ($3.70) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/15/insider-buying-flexion-therapeutics-inc-flxn-insider-purchases-1000-shares-of-stock.html.

A number of equities research analysts recently issued reports on FLXN shares. Cantor Fitzgerald set a $40.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research report on Monday, May 22nd. Zacks Investment Research downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Janney Montgomery Scott reissued a “buy” rating and set a $35.00 price target (up previously from $30.00) on shares of Flexion Therapeutics in a research report on Wednesday, July 12th. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $44.00 price target on shares of Flexion Therapeutics in a research report on Friday, July 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $31.50.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FLXN. Fiduciary Trust Co. purchased a new position in shares of Flexion Therapeutics during the 2nd quarter valued at $101,000. IFP Advisors Inc grew its position in shares of Flexion Therapeutics by 24.5% during the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,000 shares in the last quarter. Advisor Group Inc. grew its position in shares of Flexion Therapeutics by 205.9% during the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares in the last quarter. Voya Investment Management LLC grew its position in shares of Flexion Therapeutics by 25.8% during the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after purchasing an additional 2,651 shares in the last quarter. Finally, BB&T Securities LLC purchased a new position in shares of Flexion Therapeutics during the 2nd quarter valued at $289,000. Hedge funds and other institutional investors own 82.75% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.